The global meniscal repair market was valued at over $600 million in 2025. The market is expected to grow at a compound annual growth rate (CAGR) of 3.5%, reaching just under $800 million by 2032.
This report covers implants, sutures, and hybrid devices used in meniscal repair procedures. It quantifies unit sales, procedure numbers, average selling prices (ASPs), market values, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.
The market is shaped by a steady frequency of meniscal injuries and the specific medical criteria that determine surgical candidacy. Long-term success is closely tied to patient selection accuracy and surgical technique, and complete regeneration of damaged meniscal tissue remains a significant clinical challenge due to the tissue's limited natural healing capacity. Bioinductive augmentation approaches are increasingly being used to stimulate a more robust biological response in the avascular zones of the meniscus.
A clear shift from meniscectomy toward tissue preservation is defining the market's growth trajectory. The Save the Meniscus philosophy is driving rapid product development in all-inside repair systems, biological scaffolds, and knotless fixation technologies, with all-inside techniques now accounting for over 60% of annual global meniscal surgeries.
The Save the Meniscus movement has firmly established tissue preservation as the preferred clinical philosophy over meniscectomy. In leading markets, repair volumes for traumatic tears have begun to surpass tissue removal procedures, driving rapid innovation in all-suture systems, all-inside delivery devices, and biological scaffolds designed to enhance healing in avascular zones. This shift is intensifying competition across all three product categories as manufacturers work to expand the range of tear types and patient profiles eligible for repair.
All-inside repair systems have emerged as the dominant surgical format globally. These systems prioritize minimal tissue disruption, easier access to tight joint spaces such as the posterior horn, and procedural efficiency that aligns with the operational demands of ambulatory surgery centers. Inside-out suture techniques remain relevant for complex medial tears where implant access is limited, but they have become increasingly specialized as all-inside implants improve in reach, fixation strength, and delivery precision. All-inside systems now account for over 60% of annual global meniscal surgeries.
Bioinductive augmentation is an emerging growth area within the market. Implants designed to stimulate biological healing in avascular zones directly address one of the fundamental limitations of meniscal repair, where restricted vascularity limits the natural repair response. As clinical evidence for these technologies grows and integration with all-inside and hybrid platforms improves, bioinductive approaches are expected to expand the pool of tears that surgeons consider repairable rather than amenable only to partial tissue removal.
Arthrex remains the second leading competitor in the meniscal repair market in 2025. The company's all-inside portfolio is led by the FiberStitch 1.5 implant, which uses soft all-suture sheaths and a low-profile 1.5 mm needle to minimize tissue trauma and morbidity. The Meniscal Cinch II linear delivery system provides high-strength knotless fixation using 2-0 FiberWire. For complex cases, the Knee Scorpion suture passer supports suture passage in tight joint spaces, and the ZoneNavigator system serves inside-out procedures using 0.9 mm SutureTape. A significant 2025 addition is the SutureLoc implant, a knotless all-suture solution for reproducible meniscal root repair without requiring a posterior medial portal.
CONMED maintains a strong position in the market through its expanding joint preservation portfolio. The Infinity AIM Meniscal Repair Device features a hidden implant design that minimizes piercing diameter during deployment. The Sequent Meniscal Repair Device offers PEEK implants and Hi-Fi suture for up to six continuous stitches in a knotless configuration. For inside-out techniques, the Zone Specific II system targets anterior, middle, and posterior zone tears, while the BioBrace reinforced bioinductive implant is increasingly used to augment these repairs.
6 charts and 25 figures illustrating market segmentation and performance metrics.
Methodology Appendix, Abbreviation and Acronym Glossary explaining all data definitions and modeling assumptions.
Licensing options: single-user, site, and enterprise.
This report covers implants, sutures, and hybrid devices used in meniscal repair procedures. It quantifies unit sales, procedure numbers, average selling prices (ASPs), market values, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.
The market is shaped by a steady frequency of meniscal injuries and the specific medical criteria that determine surgical candidacy. Long-term success is closely tied to patient selection accuracy and surgical technique, and complete regeneration of damaged meniscal tissue remains a significant clinical challenge due to the tissue's limited natural healing capacity. Bioinductive augmentation approaches are increasingly being used to stimulate a more robust biological response in the avascular zones of the meniscus.
A clear shift from meniscectomy toward tissue preservation is defining the market's growth trajectory. The Save the Meniscus philosophy is driving rapid product development in all-inside repair systems, biological scaffolds, and knotless fixation technologies, with all-inside techniques now accounting for over 60% of annual global meniscal surgeries.
Market Overview
The global meniscal repair market is a well-defined segment within orthopedic sports medicine, supported by a steady incidence of meniscal tears across active and aging populations. The market is shaped by the intersection of injury frequency, strict patient selection criteria, and the technical complexity of achieving durable repair in tissue with limited natural regenerative capacity. Not all meniscal tears meet the anatomical and vascular criteria required for successful repair, and long-term outcomes are closely tied to accurate patient selection and the precision of the repair technique.The Save the Meniscus movement has firmly established tissue preservation as the preferred clinical philosophy over meniscectomy. In leading markets, repair volumes for traumatic tears have begun to surpass tissue removal procedures, driving rapid innovation in all-suture systems, all-inside delivery devices, and biological scaffolds designed to enhance healing in avascular zones. This shift is intensifying competition across all three product categories as manufacturers work to expand the range of tear types and patient profiles eligible for repair.
All-inside repair systems have emerged as the dominant surgical format globally. These systems prioritize minimal tissue disruption, easier access to tight joint spaces such as the posterior horn, and procedural efficiency that aligns with the operational demands of ambulatory surgery centers. Inside-out suture techniques remain relevant for complex medial tears where implant access is limited, but they have become increasingly specialized as all-inside implants improve in reach, fixation strength, and delivery precision. All-inside systems now account for over 60% of annual global meniscal surgeries.
Bioinductive augmentation is an emerging growth area within the market. Implants designed to stimulate biological healing in avascular zones directly address one of the fundamental limitations of meniscal repair, where restricted vascularity limits the natural repair response. As clinical evidence for these technologies grows and integration with all-inside and hybrid platforms improves, bioinductive approaches are expected to expand the pool of tears that surgeons consider repairable rather than amenable only to partial tissue removal.
Market Drivers
Meniscal Preservation
The Save the Meniscus movement has solidified tissue preservation as the preferred surgical philosophy, shifting the balance from meniscectomy toward repair for an expanding range of tear types. While some variation in short-term functional outcomes between repair and removal persists, long-term evidence increasingly supports preservation as the superior strategy for preventing joint degeneration. In leading markets, repair volumes for traumatic tears have now begun to surpass removal procedures. This shift is driving rapid product development in all-suture systems and biological scaffolds designed to enhance healing in avascular zones where natural repair capacity is most limited. As repair indications expand and clinical confidence in preservation outcomes strengthens, this movement is expected to remain the primary commercial driver for the market through the forecast period.Improved Technologies and Product Advancements
Significant advances in biomaterials, cell-based technologies, and 3D printing are expanding the range of treatable tear patterns and improving outcomes for complex cases. A notable development in March 2025 involved a 3D-printed customizable hydrogel designed to treat localized tears by matching the stiffness and biochemical properties of the patient's native tissue, representing a step toward more personalized and biologically active repair solutions. Long-term clinical data from Smith and Nephew's STITCH study has reinforced the viability of repairing complex tear types such as horizontal cleavage tears, with the NOVOSTITCH Pro demonstrating high healing rates and improved patient-reported outcomes at five-year follow-up. The continued refinement of all-inside techniques, knotless delivery systems, and low-profile implant designs is expected to sustain the dominance of implant-based repair while gradually extending the clinical indications for preservation over removal.Market Limiters
Contraindications and Patient Selection
The meniscal repair market is naturally limited by the relatively stable incidence rate of meniscal tears and the strict contraindications that govern surgical candidacy. Careful patient selection based on tear type, location, tissue vascularity, and associated knee pathology remains the most critical determinant of surgical success and rehabilitation outcome. Complete regeneration of damaged meniscal tissue is difficult to achieve due to the tissue's inherently limited healing capacity, particularly in avascular zones. While bioinductive implants such as the REGENETEN Bioinductive Implant are helping to address these healing limitations by stimulating a stronger biological response, they do not fully eliminate the contraindications built into the tissue's biology, keeping the addressable procedure population constrained relative to the broader prevalence of meniscal pathology.Increased Operation Time for Suture Techniques
Inside-out suture meniscal repair offers versatility across tear types but requires longer operative times compared to all-inside implant systems, limiting its growth relative to faster alternatives. The procedural speed advantage of hybrid and all-inside implant systems has driven these formats to account for over 60% of global meniscal surgeries annually, reducing suture repair to a specialized niche for cases where implant-based access is not feasible. The growing prevalence of ASC-based knee procedures reinforces this dynamic, as these facilities prioritize shorter anesthesia times, streamlined instrument sets, and efficient room turnover to maintain profitability. Structural pressure on operative time constrains the suture segment's growth potential relative to faster all-inside and hybrid alternatives.Market Coverage and Data Scope
- Quantitative coverage: Procedure numbers, market size, market shares, market forecasts, growth rates, units sold, and average selling prices.
- Qualitative coverage: Growth trends, market limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, and practice trends shaping demand.
- Time frame: Base year 2025, forecasts 2026 to 2032, historical data 2022 to 2024.
- Data sources: Primary interviews with orthopedic industry leaders and sports medicine surgeons, regulatory data, hospital and ASC procurement data, import and export data, and the iData Research internal database.
- Care settings: Hospitals, ambulatory surgery centers, and orthopedic specialty clinics.
Markets Covered and Segmentation
The meniscal repair market is analyzed across three product categories, each assessed by unit volume, ASP, and market value with historical and forecast data:
- Meniscal Repair Implants Market
- Meniscal Repair Sutures Market
- Meniscal Repair Hybrid Market
Competitive Analysis
Smith and Nephew holds the leading share of the total meniscal repair market, representing more than one-third of the global sector in 2025. This leadership is rooted in early innovation in the all-inside repair category beginning with the FasT-Fix system, which has been consistently strengthened with the FasT-Fix 360, Ultra-Fast-Fix, and the NovoStitch Pro system for complex tear patterns including radial and horizontal cleavage tears. The Fast-Fix Flex is a flagship offering and the only all-inside system featuring a surgeon-guided bendable needle and shaft, enabling access to all zones of the meniscus including the posterior horn and mid-body while minimizing chondral damage risk. Long-term data from the STITCH study has further reinforced the clinical evidence supporting these platforms.Arthrex remains the second leading competitor in the meniscal repair market in 2025. The company's all-inside portfolio is led by the FiberStitch 1.5 implant, which uses soft all-suture sheaths and a low-profile 1.5 mm needle to minimize tissue trauma and morbidity. The Meniscal Cinch II linear delivery system provides high-strength knotless fixation using 2-0 FiberWire. For complex cases, the Knee Scorpion suture passer supports suture passage in tight joint spaces, and the ZoneNavigator system serves inside-out procedures using 0.9 mm SutureTape. A significant 2025 addition is the SutureLoc implant, a knotless all-suture solution for reproducible meniscal root repair without requiring a posterior medial portal.
CONMED maintains a strong position in the market through its expanding joint preservation portfolio. The Infinity AIM Meniscal Repair Device features a hidden implant design that minimizes piercing diameter during deployment. The Sequent Meniscal Repair Device offers PEEK implants and Hi-Fi suture for up to six continuous stitches in a knotless configuration. For inside-out techniques, the Zone Specific II system targets anterior, middle, and posterior zone tears, while the BioBrace reinforced bioinductive implant is increasingly used to augment these repairs.
Technology and Practice Trends
- All-inside system dominance: All-inside implant systems now account for over 60% of annual global meniscal surgeries, favored for minimal tissue disruption, procedural speed, and compatibility with ASC workflows.
- Meniscal preservation philosophy: The Save the Meniscus movement continues to expand repair indications and drive product investment, with repair volumes surpassing meniscectomy in leading markets for traumatic tear types.
- Bioinductive augmentation: Implants designed to stimulate biological healing in avascular zones are growing in adoption and extending the range of tears suitable for preservation-focused management.
- Knotless fixation: Knotless all-inside systems are gaining ground by reducing deployment complexity and improving reproducibility, particularly for posterior horn and root access scenarios.
- 3D printing and biomaterial innovation: Customizable hydrogel scaffolds and patient-specific repair constructs represent an advancing area of product development aimed at matching individual tissue mechanical properties.
- Meniscal root repair: Purpose-built knotless systems for meniscal root attachment are broadening the surgical toolkit for cases where root integrity is central to joint preservation goals.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.Deliverables
104 pages of detailed narrative analysis, tables, and figures.6 charts and 25 figures illustrating market segmentation and performance metrics.
Methodology Appendix, Abbreviation and Acronym Glossary explaining all data definitions and modeling assumptions.
Licensing options: single-user, site, and enterprise.
Why This Report
- Where are the largest and fastest-growing opportunities within the global meniscal repair market through 2032?
- How is the Save the Meniscus preservation philosophy expanding repair indications and reshaping competitive dynamics across implant, suture, and hybrid categories?
- What role are bioinductive augmentation technologies playing in addressing avascular zone healing limitations and extending the range of repairable tears?
- How are all-inside system improvements and knotless fixation designs affecting market share distribution across the three product categories?
- What is the impact of ASC migration and operative efficiency requirements on suture-based repair growth and product selection across facilities?
- Which companies lead the market and what are their core platforms, recent clinical evidence investments, and product development priorities?
- How do patient selection criteria and biological contraindications shape the total addressable procedure volume in this market?
- What are the key risks to growth, including stable injury incidence, repair contraindications, and the continued competitive pressure from meniscectomy in specific patient profiles?
Table of Contents
Research Methodology
Meniscal Repair Market
List of Charts
List of Figures
